Crossmark Global Holdings Inc. Buys Shares of 10,421 Hims & Hers Health, Inc. (NYSE:HIMS)

Crossmark Global Holdings Inc. bought a new position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,421 shares of the company's stock, valued at approximately $308,000.

Other hedge funds also recently bought and sold shares of the company. Summit Securities Group LLC acquired a new position in Hims & Hers Health in the 4th quarter worth about $38,000. UMB Bank n.a. increased its position in Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after purchasing an additional 933 shares during the last quarter. Fifth Third Bancorp increased its position in Hims & Hers Health by 165.4% in the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock worth $46,000 after purchasing an additional 961 shares during the last quarter. Tsfg LLC acquired a new position in Hims & Hers Health in the 1st quarter worth about $46,000. Finally, US Bancorp DE increased its position in Hims & Hers Health by 346.7% in the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock worth $47,000 after purchasing an additional 1,508 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $58.40, for a total transaction of $7,482,616.80. Following the completion of the transaction, the chief executive officer owned 89,311 shares in the company, valued at approximately $5,215,762.40. This represents a 58.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 23,107 shares of the firm's stock in a transaction on Monday, June 23rd. The stock was sold at an average price of $47.25, for a total value of $1,091,805.75. Following the completion of the transaction, the chief financial officer directly owned 63,222 shares of the company's stock, valued at $2,987,239.50. The trade was a 26.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 633,126 shares of company stock worth $33,717,663 in the last quarter. 13.71% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on HIMS shares. Wall Street Zen lowered Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Truist Financial set a $45.00 price objective on Hims & Hers Health in a report on Tuesday, June 24th. TD Cowen lowered Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their price objective for the company from $44.00 to $30.00 in a report on Tuesday, April 29th. Finally, UBS Group set a $30.00 price objective on Hims & Hers Health in a report on Monday, June 23rd. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $39.58.

Hims & Hers Health Trading Down 1.1%

NYSE:HIMS traded down $0.57 during trading hours on Thursday, hitting $51.28. 4,555,527 shares of the company were exchanged, compared to its average volume of 23,983,371. The stock has a market capitalization of $11.48 billion, a price-to-earnings ratio of 74.30, a price-to-earnings-growth ratio of 1.86 and a beta of 2.02. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98. The company has a fifty day simple moving average of $53.89 and a 200 day simple moving average of $41.45.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The business's revenue was up 110.7% compared to the same quarter last year. During the same period last year, the business posted $0.05 EPS. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.